BeOne’s CLL Phase 3 puts sonrotoclax against venetoclax plus acalabrutinib

What happened

BeOne Medicines is recruiting NCT07277231, a Phase 3 study in adults with previously untreated chronic lymphocytic leukemia that compares fixed-duration sonrotoclax plus zanubrutinib with fixed-duration venetoclax plus acalabrutinib.^[1]

The study lists 500 participants, a start date of 22 January 2026, and a primary completion date in February 2031.^[1]

Its primary outcomes are progression-free survival as determined by an independent review committee and the rate of undetectable minimal residual disease at less than 10^-4 sensitivity.^[1]

The competitive signal is the comparator, not the registry status: BeOne is testing its own BCL2/BTK pairing directly against a venetoclax-containing BCL2/BTK pairing rather than against chemotherapy, monotherapy, or an obinutuzumab-based regimen.^[1]

NCT07277231 is not an isolated CLL move; BeOne is also recruiting NCT07321652, a Phase 3 Alliance for Clinical Trials in Oncology study comparing sonrotoclax plus zanubrutinib with zanubrutinib alone in untreated CLL/SLL.^[2]

The Alliance study lists sonrotoclax as a B-cell lymphoma-2 inhibitor and zanubrutinib as a kinase inhibitor blocking BTK, which places the regimen’s mechanistic test squarely on BCL2 plus BTK inhibition.^[2]

BeOne also has NCT06073821, a Phase 3 CLL study comparing sonrotoclax plus zanubrutinib with venetoclax plus obinutuzumab, and that trial is active but no longer recruiting in the supplied registry record.^[3]

A Phase 2 BeOne study, NCT06637501, is designed to support the registration plan for sonrotoclax plus zanubrutinib in previously untreated CLL and to assess the contribution of sonrotoclax to the combination’s efficacy outcome, and the supplied registry record lists it as active but no longer recruiting.^[4]

A separate BeOne Phase 1/Phase 2 study, NCT06697184, is recruiting patients with blood cancers to evaluate novel dose ramp-up schedules when initiating sonrotoclax, with tumor lysis syndrome as the primary outcome.^[5]

Outside CLL, sonrotoclax has a documented U.S. regulatory chain in relapsed or refractory mantle cell lymphoma: Drugs@FDA lists BEQALZI under NDA220711 for BeOne Medicines USA, and the FDA label excerpt says BEQALZI is indicated for adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor, under accelerated approval based on response rate and durability of response.^[7][8]

A 1 September 2026 Cancer DOI item is titled “FDA grants accelerated approval to BCL-2 inhibitor sonrotoclax for mantle cell lymphoma,” and a 13 May 2026 BeOne press item says BEQALZI, sonrotoclax, was approved by the U.S. FDA for relapsed or refractory mantle cell lymphoma.^[9][10]

ChEMBL lists SONROTOCLAX as CHEMBL5314951 with maximum phase 3.0, but the mechanism and target fields are not populated in the supplied ChEMBL context.^[6]

Why it matters

NCT07277231 changes the CLL read from “can BeOne build a sonrotoclax-zanubrutinib regimen?” to “can BeOne beat or match a venetoclax-acalabrutinib fixed-duration comparator on progression-free survival and deep molecular response?”^[1]

That is a sharper competitive question than the active but no longer recruiting Phase 3 comparison against venetoclax plus obinutuzumab, because NCT07277231 tests two fixed-duration targeted combinations in the same previously untreated CLL population.^[1][3]

The independent-review progression-free survival endpoint gives the trial a conventional efficacy anchor, while the undetectable minimal residual disease endpoint at less than 10^-4 sensitivity tests whether the regimen can produce a depth-of-response story alongside disease-control durability.^[1]

For a CLL development team, the risk is not just a future label claim; it is the possibility that BeOne uses a head-to-head Phase 3 design to define the debate around fixed-duration BCL2/BTK combinations before competitors can reduce their own uncertainty.^[1]

The 500-patient enrollment target gives the trial enough operational scale to matter strategically, but the registry’s February 2031 primary completion date means the definitive public answer is not near-term on the supplied record.^[1]

BeOne’s broader program architecture also matters because NCT07321652 asks whether sonrotoclax adds enough to zanubrutinib alone, while NCT06637501 is explicitly designed to support the registration plan and assess sonrotoclax’s contribution to efficacy.^[2][4]

That contribution question is central: if the combination’s advantage is not separable from zanubrutinib’s activity, the strategic value of sonrotoclax in first-line CLL weakens; if the contribution is clear, BeOne has a more defensible combination thesis.^[2][4]

The tumor lysis syndrome ramp-up study adds a practical development layer, because BCL2 inhibition in blood cancers creates a dosing-initiation question that can affect regimen convenience, adoption friction, and trial execution.^[5]

The supplied BeOne 8-K exhibit gives the company a commercial context for sustained hematology investment: Q2 2026 total global revenues were $1.7 billion, BRUKINSA global revenues were $1.2 billion, and R&D expenses increased because early clinical programs advanced into late stage and preclinical programs entered the clinic.^[12]

That disclosure does not prove how much BeOne is spending on NCT07277231, but it supports the narrower point that BeOne has a scaled hematology revenue base and is advancing programs into later-stage development.^[12]

Who is exposed or gained

The directly exposed programs are fixed-duration CLL regimens that rely on venetoclax-containing combinations, because NCT07277231 names venetoclax plus acalabrutinib as the comparator in previously untreated CLL.^[1]

Zanubrutinib gains optionality inside BeOne’s own CLL franchise because the program tests it both as part of a sonrotoclax combination against venetoclax-containing combinations and against zanubrutinib monotherapy in untreated CLL/SLL.^[1][2][3]

Sonrotoclax gains strategic breadth if the CLL program reads coherently across the head-to-head comparator trial, the zanubrutinib-alone contribution trial, the venetoclax-obinutuzumab comparator trial, and the registration-supporting Phase 2 study.^[1][2][3][4]

The supplied dossier does not establish which companies, beyond the named comparator drugs and BeOne, are commercially exposed, so Prognyx does not infer a company-by-company share shift from these public records.^[1]

What we could not verify

Prognyx could not confirm public CLL efficacy results from the supplied primary registry records, because NCT07277231, NCT07321652, NCT06073821, and NCT06637501 all show no posted results in the provided dossier.^[1][2][3][4]

A CancerNetwork item reports in its title that sonrotoclax plus zanubrutinib achieved greater than 90% undetectable minimal residual disease in treatment-naive CLL/SLL, but the supplied context does not include the underlying conference abstract, company release, trial identifier, denominator, follow-up, or response-assessment details.^[11]

No BeOne press release or SEC excerpt in the supplied dossier directly announces NCT07277231, its comparator choice, or its Phase 3 start, so the head-to-head CLL trial thesis rests on ClinicalTrials.gov for the trial-specific facts.^[1]

The supplied DailyMed excerpt identifies BEQALZI’s relapsed or refractory mantle cell lymphoma indication but does not itself name sonrotoclax in the excerpt provided; the sonrotoclax-BEQALZI link in this dossier comes from the BeOne press item and the Cancer DOI title.^[8][9][10]

What to watch next

NCT07277231 lists a primary completion date in February 2031.^[1]

Before that primary completion date, the most useful public signals would be registry updates to enrollment, protocol details, endpoint timing, or posted results, because the current NCT07277231 record shows recruiting status and no results.^[1]

NCT07321652 should be watched as the cleanest contribution-of-combination test against zanubrutinib alone in untreated CLL/SLL, because the trial directly compares sonrotoclax plus zanubrutinib with zanubrutinib monotherapy.^[2]

NCT06073821 should be watched because it already tests sonrotoclax plus zanubrutinib against venetoclax plus obinutuzumab and is active but no longer recruiting in the supplied registry record.^[3]

NCT06637501 should be watched because its stated design supports the registration plan for sonrotoclax plus zanubrutinib in previously untreated CLL and assesses sonrotoclax’s contribution to the combination’s efficacy outcome.^[4]

NCT06697184 should be watched for operational read-through, because its primary outcome is tumor lysis syndrome during novel sonrotoclax dose ramp-up schedules in blood cancers.^[5]

No PDUFA date, EMA review clock, accelerated-assessment timeline, or CLL regulatory filing date is supplied for sonrotoclax in CLL, so Prognyx does not assign a CLL regulatory decision window from this dossier.^[1][2][3][4]

The now-what

First, competitors with fixed-duration CLL combinations should benchmark their own trial designs against NCT07277231’s two primary questions: independent-review progression-free survival and undetectable minimal residual disease below 10^-4 sensitivity.^[1]

If a rival program cannot compete on both durability and depth, its development narrative may need to shift toward safety, dosing convenience, patient segment, or sequencing rather than a broad efficacy contest.^[1][5]

Second, BD teams should treat NCT07321652 and NCT06637501 as risk-reduction watches, not side studies, because they address whether sonrotoclax contributes enough beyond zanubrutinib to justify the combination strategy.^[2][4]

A clean contribution signal would make sonrotoclax more than a companion to BeOne’s BTK franchise; a weak contribution signal would narrow the strategic rationale for partnering around the BCL2 component.^[2][4]

Third, clinical teams should monitor NCT06697184 because dose ramp-up and tumor lysis syndrome management can change the practical competitiveness of a BCL2-based regimen even before the pivotal efficacy question resolves.^[5]

The falsifiable read is simple: BeOne has built a multi-trial first-line CLL program around sonrotoclax plus zanubrutinib, and NCT07277231 is the direct fixed-duration comparator trial that will determine whether that program can challenge venetoclax-based combinations on both progression-free survival and molecular depth.^[1][2][3][4]

Verdict: medium-to-high strategic threat, long evidence window, with action needed now on comparator positioning, contribution-of-component monitoring, and regimen-friction defenses before the February 2031 primary-completion horizon.^[1][2][4][5]